| Literature DB >> 26171855 |
Se Joon Woo1, Jeeyun Ahn2, Margaux A Morrison3, So Yeon Ahn4, Jaebong Lee4, Ki Woong Kim5, Margaret M DeAngelis3, Kyu Hyung Park1.
Abstract
PURPOSE: To investigate the association of genetic and environmental factors, and their interactions in Korean patients with exudative age-related macular degeneration (AMD).Entities:
Mesh:
Year: 2015 PMID: 26171855 PMCID: PMC4501798 DOI: 10.1371/journal.pone.0132771
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Representative fundus and angiography images of the three age-related macular degeneration subtypes.
(A) Typical choroidal neovascularization with surrounding subretinal hemorrhage (white arrow) and evident dye leakage (white arrow) on fluorescein angiography. (B) Polypoidal choroidal vasculopathy showing reddish-orange polyp-like structures (white arrows) and branching choroidal vascular network with polypoidal vascular endings (arrowheads). (C) Retinal angiomatous proliferation with multiple drusen, pinpoint subretinal hemorrhage (white arrow) and chorioretinal anastomosis (white arrow) demonstrated on indocyanine green angiography.
Distribution of non-genetic variables among studied subjects.
| Exudative AMD | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Control (N = 395) | Exudative AMD (N = 314) | PCV (N = 111) | Typical CNV (N = 154) | PCV vs. Typical CNV | ||||||
| Variables | N | (%) | N | (%) | P | N | (%) | N | (%) | P |
| Age (yr) | 68.20±10.13 | 71.1±8.4 | <0.001 | 67.35±7.34 | 72.56±8.10 | <0.001 | ||||
| Male sex | 198 | (50) | 164 | (52) | 0.578 | 61 | (55) | 86 | (56) | 0.886 |
| Smoking | ||||||||||
| (1) Never | 228 | (58) | 145 | (46) | 40 | (36) | 78 | (51) | ||
| Ex- | 128 | (32) | 121 | (39) | 54 | (49) | 53 | (34) | ||
| Current | 39 | (10) | 47 | (15) | 0.007 | 17 | (15) | 23 | (15) | 0.042 |
| (2) Never | 228 | (58) | 145 | (46) | 40 | (36) | 78 | (51) | ||
| Ever | 167 | (42) | 168 | (54) | 0.003 | 71 | (64) | 76 | (49) | 0.018 |
| Education (yr) | ||||||||||
| <9 | 91 | (23) | 70 | (22) | 12 | (11) | 41 | (27) | ||
| <12 | 54 | (14) | 41 | (13) | 12 | (11) | 24 | (16) | ||
| <15 | 122 | (31) | 83 | (27) | 32 | (29) | 38 | (25) | ||
| ≥15 | 128 | (32) | 119 | (38) | 0.423 | 55 | (50) | 51 | (33) | 0.003 |
| BMI (kg/m2) | 23.61±2.96 | 23.47±3.11 | 0.542 | 23.47±2.80 | 23.66±3.37 | 0.638 | ||||
| Diabetes | 87 | (22) | 62 | (20) | 0.462 | 16 | (14) | 28 | (18) | 0.416 |
| Hypertension | 182 | (46) | 164 | (52) | 0.101 | 54 | (49) | 90 | (58) | 0.114 |
| Cerebrovascular accident | 40 | (10) | 43 | (14) | 0.199 | 10 | (9) | 23 | (15) | 0.149 |
| Hyperlipidemia | 82 | (21) | 52 | (17) | 0.134 | 22 | (20) | 21 | (14) | 0.178 |
| Spherical Equivalent (D) | -0.407±3.13 | 0.581±1.81 | <0.001 | 0.414±1.72 | 0.502±1.90 | 0.737 | ||||
| Myopia | 36 | (28) | 38 | (17) | 0.014 | 16 | (18) | 31 | (21) | 1.000 |
| Axial Length (OU) | 23.64±1.3 | 23.60±1.1 | 0.756 | 23.57±0.9 | 23.44±1.1 | 0.521 | ||||
| Axial Length (OD) | 23.66±1.3 | 23.58±1.1 | 0.613 | 23.61±0.9 | 23.50±1.1 | 0.310 | ||||
Abbreviations: AMD, age-related macular degeneration; PCV, polypoidal choroidal vasculopathy; CNV, choroidal neovascularization without PCV; BMI, Body Mass Index; D, diopters; OU, oculus uterque (both eyes); OD, oculus dexter (the right eye).
*comparison with controls,
°calculated only in phakic eyes
Significant Association Results from PLINK comparing Exudative AMD vs. Normal.
| CHR | SNP | BP | A1 | Freq (A) | Freq (U) | A2 | CHISQ | Odds Ratio (95% CI) | UNADJ p | GC p | BONF p | FDR_BH p |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | rs800292 | 194908856 | T | 0.290 | 0.401 | C | 18.06 | 0.612 (0.4876–0.7681) | 2.14E-05 | 0.0076 | 0.0018 | 0.0006 |
| 10 | rs2736911 | 124204345 | C | 0.898 | 0.833 | T | 11.77 | 1.755 (1.269–2.427) | 0.0006 | 0.0311 | 0.0493 | 0.0123 |
| 10 | rs10490924 | 124204438 | T | 0.654 | 0.396 | G | 90.05 | 2.881 (2.309–3.595) | 2.32E-21 | 2.52E-09 | 1.91E-19 | 1.91E-19 |
| 10 | rs11200638 | 124210534 | A | 0.655 | 0.402 | G | 86.71 | 2.825 (2.264–3.524) | 1.26E-20 | 4.95E-09 | 1.03E-18 | 5.15E-19 |
SNPs shown above are those that remained significant after correction for multiple testing.
Abbreviations: CHR, chromosome; SNP, Single Nucleotide Polymorphism; BP, base pairs; A1, allele 1; Freq (A), frequency of allele 1 in affecteds; Freq (U) frequency of allele 1 in unaffecteds; A2, allele 2; CHISQ, Chi Square value; C.I., confidence interval; GC, Genomic-control; BONF, Bonferroni single-step adjusted; HOLM, Holm (1979) step-down adjusted; SIDAK SS, Sidak single-step adjusted; SIDAK SD, Sidak step-down adjusted; FDR BH, Benjamini & Hochberg (1995) step-up FDR control), and FDR BY (Benjamini & Yekutieli (2001) step-up FDR control).
Significant Association Results from PLINK comparing CNV vs. Normal.
| CHR | SNP | BP | A1 | Freq (A) | Freq (U) | A2 | CHISQ | Odds Ratio (95% CI) | UNADJ p | GC p | BONF p | FDR_BH p |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 10 | rs10490924 | 124204438 | T | 0.637 | 0.396 | G | 51.35 | 2.684(2.04–3.532) | 7.73E-13 | 1.48E-04 | 6.34E-11 | 6.34E-11 |
| 10 | rs11200638 | 124210534 | A | 0.637 | 0.402 | G | 48.55 | 2.612 (1.986–3.436) | 3.22E-12 | 2.25E-04 | 2.64E-10 | 1.32E-10 |
SNPs shown above are those that remained significant after correction for multiple testing.
Abbreviations: CHR, chromosome; SNP, Single Nucleotide Polymorphism; BP, base pairs; A1, allele 1; Freq (A), frequency of allele 1 in affecteds; Freq (U) frequency of allele 1 in unaffecteds; A2, allele 2; CHISQ, Chi Square value; C.I., confidence interval; GC, Genomic-control; BONF, Bonferroni single-step adjusted; HOLM, Holm (1979) step-down adjusted; SIDAK SS, Sidak single-step adjusted; SIDAK SD, Sidak step-down adjusted; FDR BH, Benjamini & Hochberg (1995) step-up FDR control), and FDR BY (Benjamini & Yekutieli (2001) step-up FDR control).
Significant Association Results from PLINK comparing PCV vs. Normal.
| CHR | SNP | BP | A1 | Freq (A) | Freq (U) | A2 | CHISQ | Odds Ratio (95% CI) | UNADJ p | GC p | BONF p | FDR_BH p |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 10 | rs10490924 | 124204438 | T | 0.637 | 0.396 | G | 39.08 | 2.679 (1.955–3.672) | 4.08E-10 | 2.36E-06 | 3.34E-08 | 3.34E-08 |
| 10 | rs11200638 | 124210534 | A | 0.637 | 0.402 | G | 36.91 | 2.607 (1.903–3.572) | 1.24E-09 | 4.50E-06 | 1.01E-07 | 5.06E-08 |
SNPs shown above are those that remained significant after correction for multiple testing.
Abbreviations: CHR, chromosome; SNP, Single Nucleotide Polymorphism; BP, base pairs; A1, allele 1; Freq (A), frequency of allele 1 in affecteds; Freq (U) frequency of allele 1 in unaffecteds; A2, allele 2; CHISQ, Chi Square value; C.I., confidence interval; GC, Genomic-control; BONF, Bonferroni single-step adjusted; HOLM, Holm (1979) step-down adjusted; SIDAK SS, Sidak single-step adjusted; SIDAK SD, Sidak step-down adjusted; FDR BH, Benjamini & Hochberg (1995) step-up FDR control), and FDR BY (Benjamini & Yekutieli (2001) step-up FDR control).
Association of non-genetic risk factors using logistic regression.
| Exudative vs. Normal | CNV vs. Normal | PCV vs. Normal | PCV vs. CNV | |||||
|---|---|---|---|---|---|---|---|---|
| Variable | Odds Ratio (95% C.I.) | p value | Odds Ratio (95% C.I.) | p value | Odds Ratio (95% C.I.) | p value | Odds Ratio (95% C.I.) | p value |
| Age (years) | 1.034 (1.017–1.051) | 5.25E-05 | 1.049 (1.028–1.071) | 3.76E-06 | 0.99 (0.969–1.012) | 0.3913 | 0.917 (0.886–0.949) | 7.50E-07 |
| BMI (kg/m2) | 0.985 (0.937–1.035) | 0.5420 | 1.005 (0.946–1.068) | 0.8759 | 0.984 (0.915–1.058) | 0.6603 | 0.981 (0.908–1.061) | 0.6378 |
| Cerebrovascular accident | 1.317 (0.834–2.079) | 0.2376 | 1.43 (0.826–2.475) | 0.2013 | 0.811 (0.392–1.675) | 0.5708 | 0.567 (0.258–1.244) | 0.1571 |
| Diabetes | 0.872 (0.605–1.257) | 0.4619 | 0.806 (0.504–1.287) | 0.3662 | 0.588 (0.329–1.051) | 0.0730 | 0.73 (0.375–1.42) | 0.3537 |
| Education | 1.058 (0.93–1.204) | 0.3891 | 0.939 (0.801–1.101) | 0.4355 | 1.475 (1.199–1.816) | 0.0002 | 1.537 (1.224–1.93) | 0.0002 |
| Hypertension | 1.282 (0.952–1.726) | 0.1015 | 1.588 (1.092–2.309) | 0.0154 | 1.085 (0.712–1.651) | 0.7052 | 0.683 (0.419–1.112) | 0.1254 |
| Hyperlipidemia | 0.748 (0.509–1.099) | 0.1396 | 0.584 (0.347–0.983) | 0.0429 | 0.971 (0.578–1.631) | 0.9110 | 1.661 (0.868–3.18) | 0.1254 |
| Female sex | 0.919 (0.683–1.237) | 0.5781 | 0.809 (0.558–1.172) | 0.2624 | 0.84 (0.552–1.28) | 0.4179 | 1.039 (0.638–1.691) | 0.8773 |
| Spherical Equivalent (SE) | 1.187 (1.078–1.307) | 0.0005 | 1.157 (1.031–1.297) | 0.0128 | 1.145 (1.013–1.295) | 0.0307 | 0.974 (0.834–1.136) | 0.7347 |
| Myopia | 0.506 (0.301–0.850) | 0.0101 | 0.517 (0.274–0.977) | 0.0421 | 0.553 (0.285–1.073) | 0.0799 | 1.069 (0.510–2.242) | 0.8595 |
| Axial Length (Average) | 0.970 (0.802–1.174) | 0.7551 | 0.904 (0.701–1.166) | 0.4368 | 1.005 (0.756–1.336) | 0.9730 | 1.142 (0.765–1.706) | 0.5167 |
| Axial Length (OD) | 0.952 (0.786–1.153) | 0.6125 | 0.860 (0.659–1.121) | 0.2644 | 1.022 (0.773–1.351) | 0.8802 | 1.232 (0.825–1.840) | 0.3083 |
| Smoking (2 Level) | 1.582 (1.173–2.132) | 0.0026 | 1.297 (0.894–1.882) | 0.1707 | 2.364 (1.533–3.646) | 9.89E-05 | 1.823 (1.11–2.994) | 0.0178 |
| Smoking (3 Level) | 1.408 (1.136–1.745) | 0.0018 | 1.263 (0.97–1.645) | 0.0826 | 1.718 (1.276–2.313) | 0.0004 | 1.345 (0.956–1.891) | 0.0886 |
PCV = polypoidal choroidal vasculopathy, CNV = choroidal neovascularization without PCV, C.I. = confidence interval, BMI = Body Mass Index
°calculated only in phakic eyes
Final stepwise regression model for Exudative AMD vs. Normal.
| Risk Factor | Exudative AMD vs. Normal | |
|---|---|---|
| Odds Ratio (95% C.I.) | p value | |
| Age | 1.059 (1.027–1.092) | 0.0002 |
| Spherical Equivalent | 1.198 (1.068–1.344) | 0.0021 |
| Smoking3 | 1.528 (1.044–2.236) | 0.0289 |
| CFH rs800292 (add) | 0.567 (0.393–0.818) | 0.0024 |
| ARMS2 rs10490924 (add) | 2.664 (1.881–3.772) | 3.39E-08 |
Final stepwise regression models were constructed using risk factors that were shown to be significant in single factor analysis (p < .05).
Abbreviations: C.I., confidence interval; Smoking3, Current/Ex/Never smoking; add, additive genetic model.
°calculated only in phakic eyes
Final stepwise regression model for PCV vs. CNV.
| Risk Factor | PCV vs. CNV | |
|---|---|---|
| Odds Ratio (95% C.I.) | p value | |
| Age | 0.914 (0.880–0.949) | 2.65E-06 |
| BMI | 0.891 (0.812–0.979) | 0.0159 |
| Education | 1.457 (1.134–1.872) | 0.0032 |
Final stepwise regression models were constructed using risk factors that were shown to be significant in single factor analysis (p < .05).
Abbreviations: C.I., confidence interval; BMI, body mass index.
Final stepwise regression model for CNV vs. Normal.
| Risk Factor | CNV vs. Normal | |
|---|---|---|
| Odds Ratio (95% C.I.) | p value | |
| Age | 1.075 (1.038–1.114) | 6.82E-05 |
| Hyperlipidemia | 0.405 (0.191–0.859) | 0.0185 |
| Spherical Equivalent | 1.188 (1.037–1.361) | 0.0128 |
| ARMS rs10490924 (add) | 2.527 (1.674–3.814) | 1.03E-05 |
Final stepwise regression models were constructed using risk factors that were shown to be significant in single factor analysis (p < .05).
Abbreviations: C.I., confidence interval; add, additive genetic model.
°calculated only in phakic eyes
Final stepwise regression model for PCV vs. Normal.
| Risk Factor | PCV vs. Normal | |
|---|---|---|
| Odds Ratio (95% C.I.) | p value | |
| Smoking2 | 2.460 (1.359–4.453) | 0.0030 |
| Spherical Equivalent | 1.187 (1.033–1.364) | 0.0156 |
| ARMS2 rs10490924 (add) | 2.382 (1.549–3.664) | 7.79E-05 |
Final stepwise regression models were constructed using risk factors that were shown to be significant in single factor analysis (p < .05).
Abbreviations: C.I., confidence interval; Smoking2, Ever/Never smoking; add, additive genetic model.
°calculated only in phakic eyes